Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases

키워드

참고문헌 (206)

1. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
2. Polyzos SA, "Obesity and nonalcoholic fatty liver disease : From pathophysiology to therapeutics", Metabolism, 92, pp.82~97 (2019)
3. Younossi ZM, "The global epidemiology of NAFLD and NASH in patients with type 2 diabetes : A systematic review and meta-analysis", J Hepatol, 71, pp.793~801 (2019)
4. Ampuero J, "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH", J Hepatol, 73, pp.17~25 (2020)
5. Powell EE, "Non-alcoholic fatty liver disease", Lancet, 397, pp.2212~2224 (2021)
6. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : Systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
7. Sheka AC, "Nonalcoholic steatohepatitis : A review", JAMA, 323, pp.1175~1183 (2020)
8. Duell PB, "Nonalcoholic fatty liver disease and cardiovascular risk : A scientific statement from the american heart association", Arterioscler Thromb Vasc Biol, 42, pp.e168~e185 (2022)
9. Zhou XD, "An international multidisciplinary consensus statement on MAFLD and the risk of CVD", Hepatol Int, 17, pp.773~791 (2023)
10. Davis TME, "Diabetes and metabolic dysfunction-associated fatty liver disease", Metabolism, 123, pp.154868~ (2021)
11. Shih CI, "Severity of fatty liver is highly correlated with the risk of hypertension and diabetes : a cross-sectional and longitudinal cohort study", Hepatol Int (2023)[DOI]
12. Jarvis H, "Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease(NAFLD) : A systematic review and meta-analysis of population-based observational studies", PLoS Med, 17, pp.e1003100~ (2020)
13. Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : An international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
14. Khalifa A, "The utility of liver biopsy in 2020", Curr Opin Gastroenterol, 36, pp.184~191 (2020)
15. Hernaez R, "Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver : a meta-analysis", Hepatology, 54, pp.1082~1090 (2011)
16. Sasso M, "Controlled attenuation parameter(CAP) : a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis : preliminary study and validation in a cohort of patients with chronic liver disease from various causes", Ultrasound Med Biol, 36, pp.1825~1835 (2010)
17. Middleton MS, "Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis", Gastroenterology, 153, pp.753~761 (2017)
18. Bedogni G, "The fatty liver index : a simple and accurate predictor of hepatic steatosis in the general population", BMC Gastroenterol, 6, pp.33~ (2006)
19. Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease", Dig Liver Dis, 42, pp.503~508 (2010)
20. Kotronen A, "Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors", Gastroenterology, 137, pp.865~872 (2009)
21. Bedogni G, "A simple index of lipid overaccumulation is a good marker of liver steatosis", BMC Gastroenterol, 10, pp.98~ (2010)
22. Stern C, "Non-invasive diagnosis of hepatic steatosis", Hepatol Int, 11, pp.70~78 (2017)
23. Day CP, "Steatohepatitis : a tale of two"hits"?", Gastroenterology, 114, pp.842~845 (1998)
24. Sakurai Y, "Role of Insulin Resistance in MAFLD", Int J Mol Sci, 22, pp.4156~ (2021)
25. Li S, "Bifurcation of insulin signaling pathway in rat liver : mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis", Proc Natl Acad Sci U S A, 107, pp.3441~3446 (2010)
26. Jorge ASB, "Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity", Obes Res Clin Pract, 12(Suppl 2), pp.1~8 (2018)
27. DI Maira G, "Liver fibrosis in the context of nonalcoholic steatohepatitis : the role of adipokines", Minerva Gastroenterol Dietol, 64, pp.39~50 (2018)
28. Marra F, "Lipotoxicity and the gut-liver axis in NASH pathogenesis", J Hepatol, 68, pp.280~295 (2018)
29. Wu H, "Metabolic inflammation and insulin resistance in obesity", Circ Res, 126, pp.1549~1564 (2020)
30. Parry SA, "Intrahepatic fat and postprandial glycemia increase after consumption of a diet enriched in saturated fat compared with free sugars", Diabetes Care, 43, pp.1134~1141 (2020)
31. Ziolkowska S, "The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease", Int J Mol Sci, 22, pp.11128~ (2021)
32. Farrell GC, "Nonalcoholic fatty liver disease : from steatosis to cirrhosis", Hepatology, 43(2 Suppl 1), pp.S99~S112 (2006)
33. Starley BQ, "Nonalcoholic fatty liver disease and hepatocellular carcinoma : a weighty connection", Hepatology, 51, pp.1820~1832 (2010)
34. Eslam M, "Genetics and epigenetics of NAFLD and NASH : Clinical impact", J Hepatol, 68, pp.268~279 (2018)
35. Oh JH, "Characterization of gut microbiome in Korean patients with metabolic associated fatty liver disease", Nutrients, 13, pp.1013~ (2021)
36. Hernández-Ceballos W, "Gut microbiota in metabolic-associated fatty liver disease and in other chronic metabolic diseases", J Clin Transl Hepatol, 9, pp.227~238 (2021)
37. Fang YL, "Pathogenesis of nonalcoholic fatty liver disease in children and adolescence : From"two hit theory"to"multiple hit model"", World J Gastroenterol, 24, pp.2974~2983 (2018)
38. Stols-Gonçalves D, "NAFLD and atherosclerosis : Two sides of the same dysmetabolic coin?", Trends Endocrinol Metab, 30, pp.891~902 (2019)
39. Umpleby AM, "Impact of liver fat on the differential partitioning of hepatic triacylglycerol into VLDL subclasses on high and low sugar diets", Clin Sci(Lond), 131, pp.2561~2573 (2017)
40. Zou H, "Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China : a systematic review", Hepatol Int, 16, pp.27~37 (2022)
41. Tsai TY, "Association between coronary artery plaque progression and liver fibrosis biomarkers in population with low calcium scores", Nutrients, 14, pp.3163~ (2022)
42. Balta S, "Mean platelet volume as a surrogate marker of long-term mortality in patients undergoing percutaneous coronary intervention", Am J Cardiol, 112, pp.142~ (2013)
43. Drożdż K, "Metabolic-associated fatty liver disease(MAFLD), diabetes, and cardiovascular disease : Associations with fructose metabolism and gut microbiota", Nutrients, 14, pp.103~ (2021)
44. Zaiou M, "Dietary patterns influence target gene expression through emerging epigenetic mechanisms in nonalcoholic fatty liver disease", Biomedicines, 9, pp.1256~ (2021)
45. Li M, "The microbial metabolome in metabolic-associated fatty liver disease", J Gastroenterol Hepatol, 37, pp.15~23 (2022)
46. Gutiérrez-Cuevas J, "Pathophysiological molecular mechanisms of obesity : A link between MAFLD and NASH with cardiovascular diseases", Int J Mol Sci, 22, pp.11629~ (2021)
47. Lin YC, "New perspectives on genetic prediction for pediatric metabolic associated fatty liver disease", Front Pediatr, 8, pp.603654~ (2020)
48. Dongiovanni P, "Nonalcoholic fatty liver disease or metabolic dysfunctionassociated fatty liver disease diagnoses and cardiovascular diseases : From epidemiology to drug approaches", Eur J Clin Invest, 51, pp.e13519~ (2021)
49. Meroni M, "MBOAT7down-regulation by genetic and environmental factors predisposes to MAFLD", EBioMedicine, 57, pp.102866~ (2020)
50. Boeckmans J, "Infections at the nexus of metabolic-associated fatty liver disease", Arch Toxicol, 95, pp.2235~2253 (2021)
51. Huang JF, "The incidence and risks of liver biopsy in non-cirrhotic patients : An evaluation of 3806 biopsies", Gut, 56, pp.736~737 (2007)
52. Shiha G, "Asian-Pacific Association for the Study of the Liver(APASL)consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis : a 2016 update", Hepatol Int, 11, pp.1~30 (2017)
53. Anstee QM, "Impact of non-invasive biomarkers on hepatology practice : Past, present and future", J Hepatol, 76, pp.1362~1378 (2022)
54. Xiao G, "Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease : A meta-analysis", Hepatology, 66, pp.1486~1501 (2017)
55. Mózes FE, "Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis", Gut, 71, pp.1006~1019 (2022)
56. Balakrishnan M, "Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease", J Hepatol, 78, pp.493~500 (2023)
57. Kanwal F, "Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease", Gastroenterology, 161, pp.1657~1669 (2021)
58. Cusi K, "American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings : Co-sponsored by the American Association for the Study of Liver Diseases(AASLD)", Endocr Pract, 28, pp.528~562 (2022)
59. Tokushige K, "Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease", nonalcoholic steatohepatitis 2020, 2021, pp.56, 951~963
60. Zhou XD, "Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention", Cardiovasc Diabetol, 21, pp.270~ (2022)
61. Angulo P, "Long-term mortality in nonalcoholic fatty liver disease : is liver histology of any prognostic significance?", Hepatology, 51, pp.373~375 (2010)
62. Wang Y, "Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China", Front Endocrinol(Lausanne), 13, pp.968766~ (2022)
63. Anstee QM, "Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis", Nat Rev Gastroenterol Hepatol, 10, pp.330~344 (2013)
64. Kasper P, "NAFLD and cardiovascular diseases : a clinical review", Clin Res Cardiol, 110, pp.921~937 (2021)
65. Sumida Y, "Current and future pharmacological therapies for NAFLD", NASH, 2018, pp.53, 362~376
66. Godinez-Leiva E, "Nonalcoholic fatty liver disease(NAFLD)for primary care providers : Beyond the liver", Curr Hypertens Rev, 17, pp.94~111 (2021)
67. Tsou MT, "Gender-based association of coronary artery calcification and framingham risk score with non-alcoholic fatty liver disease and abdominal obesity in taiwanese adults, a cross-sectional study", Front Cardiovasc Med, 9, pp.803967~ (2022)
68. Hsiao CC, "Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis", BMC Cardiovasc Disord, 21, pp.244~ (2021)
69. Hsu PF, "The association of the steatosis severity in fatty liver disease with coronary plaque pattern in general population", Liver Int, 41, pp.81~90 (2021)
70. Wang L, "Changes in inflammatory factors and prognosis of patients complicated with non-alcoholic fatty liver disease undergoing coronary artery bypass grafting", Exp Ther Med, 15, pp.949~953 (2018)
71. Ali H, "In-hospital outcomes of patients with non-alcoholic fatty liver disease who underwent percutaneous coronary intervention : A nationwide inpatient sample analysis", Cureus, 13, pp.e17338~ (2021)
72. Shi KQ, "Nonalcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries", Mol Biol Rep, 41, pp.4713~4720 (2014)
73. Xia W, "Analysis of risk factors for adverse cardiovascular events in elderly patients with acute myocardial infarction and non-alcoholic fatty liver disease(NAFLD)", Med Sci Monit, 26, pp.e922913~ (2020)
74. Ma W, "Association of NAFLD with cardiovascular disease and all-cause mortality : a large-scale prospective cohort study based on UK Biobank", Ther Adv Chronic Dis, 13, pp.20406223221122478~ (2022)
75. Chen X, "Association of nonalcoholic fatty liver disease with ventricular tachycardia and sinus arrest in patients with non-ST-segment elevation myocardial infarction", Int Heart J, 63, pp.814~820 (2022)
76. Ma J, "Bi-directional analysis between fatty liver and cardiovascular disease risk factors", J Hepatol, 66, pp.390~397 (2017)
77. Liu P, "Bidirectional association between nonalcoholic fatty liver disease and hypertension from the Dongfeng-Tongji cohort study", J Am Soc Hypertens, 12, pp.660~670 (2018)
78. Salah HM, "Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction", JACC Basic Transl Sci, 6, pp.918~932 (2021)
79. VanWagner LB, "Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction : A population-based study", Hepatology, 62, pp.773~783 (2015)
80. Huang DQ, "Shared mechanisms between cardiovascular disease and NAFLD", Semin Liver Dis, 42, pp.455~464 (2022)
81. Zhang XJ, "Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis", Sci Transl Med, 13, pp.eabg8117~ (2021)
82. Chen B, "NAFLD in cardiovascular diseases : A contributor or comorbidity?", Semin Liver Dis, 42, pp.465~474 (2022)
83. Hung CS, "Nonalcoholic fatty liver disease is associated with QT prolongation in the general population", J Am Heart Assoc, 4, pp.e001820~ (2015)
84. Lei F, "The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China", Front Endocrinol(Lausanne), 13, pp.1007171~ (2022)
85. Decoin R, "High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation", Front Endocrinol(Lausanne), 13, pp.957245~ (2022)
86. van Kleef LA, "Liver stiffness not fatty liver disease is associated with atrial fibrillation : The Rotterdam study", J Hepatol, 77, pp.931~938 (2022)
87. Long MT, "Relations of liver fat with prevalent and incident atrial fibrillation in the framingham heart study", J Am Heart Assoc, 6, pp.e005227~ (2017)
88. Targher G, "Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic", thrombotic and vascular complications, 2013, pp.39, 214~228
89. Di Minno MN, "High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism", World J Gastroenterol, 16, pp.6119~6122 (2010)
90. Kotronen A, "Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease", Liver Int, 31, pp.176~183 (2011)
91. Targher G, "Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis", Diabetes Care, 30, pp.e31~e32 (2007)
92. Ciavarella A, "Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease", Thromb Res, 198, pp.139~150 (2021)
93. Ji D, "Letter to the Editor : Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19", Metabolism, 115, pp.154437~ (2021)
94. Northup PG, "Hypercoagulation and thrombophilia in liver disease", J Thromb Haemost, 6, pp.2~9 (2008)
95. Cotrim HP, "Liver : Does bariatric surgery reduce the severity of NAFLD?", Nat Rev Gastroenterol Hepatol, 7, pp.11~13 (2010)
96. Zhang HJ, "Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease : A randomized clinical trial", JAMA Intern Med, 176, pp.1074~1082 (2016)
97. Huang PH, "2022Taiwan lipid guidelines for primary prevention", J Formos Med Assoc, 121, pp.2393~2407 (2022)
98. Wang TD, "2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension", Acta Cardiol Sin, 38, pp.225~325 (2022)
99. Ueng KC, "2023 Guidelines of the Taiwan Society of Cardiology on the diagnosis and management of chronic coronary syndrome", Acta Cardiol Sin, 39, pp.4~96 (2023)
100. Chiang CE, "2023 Consensus of Taiwan Society of Cardiology on the pharmacological treatment of chronic heart failure", Acta Cardiol Sin, 39, pp.361~390 (2023)
101. Thoma C, "Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults : a systematic review", J Hepatol, 56, pp.255~266 (2012)
102. Vilar-Gomez E, "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis", Gastroenterology, 149, pp.367~378 (2015)
103. Wong VW, "Community-based lifestyle modification programme for non-alcoholic fatty liver disease : a randomized controlled trial", J Hepatol, 59, pp.536~542 (2013)
104. Malespin MH, "Weight loss and weight regain in usual clinical practice : Results from the TARGET-NASH observational cohort", Clin Gastroenterol Hepatol, 20, pp.2393~2395 (2022)
105. Christensen QH, "Evolution of acyl-substrate recognition by a family of acyl-homoserine lactone synthases", PLoS One, 9, pp.e112464~ (2014)
106. Mazzotti A, "An internet-based approach for lifestyle changes in patients with NAFLD : Two-year effects on weight loss and surrogate markers", J Hepatol, 69, pp.1155~1163 (2018)
107. Mouzaki M, "The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease", J Clin Gastroenterol, 46, pp.457~467 (2012)
108. Vilar-Gomez E, "High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population", Hepatology, 75, pp.1491~1506 (2022)
109. Yasutake K, "Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease : the significance of dietary cholesterol", Scand J Gastroenterol, 44, pp.471~477 (2009)
110. Meng G, "Soft drinks consumption is associated with nonalcoholic fatty liver disease independent of metabolic syndrome in Chinese population", Eur J Nutr, 57, pp.2113~2121 (2018)
111. Hall KD, "Obesity energetics : Body weight regulation and the effects of diet composition", Gastroenterology, 152, pp.1718~1727 (2017)
112. Antraco VJ, "Omega-3 polyunsaturated fatty acids prevent nonalcoholic steatohepatitis(NASH)and stimulate adipogenesis", Nutrients, 13, pp.622~ (2021)
113. European Association for the Study of the Liver(EASL), "EASL-EASDEASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
114. Eslam M, "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease", Hepatol Int, 14, pp.889~919 (2020)
115. Properzi C, "Ad libitum mediterranean and low-fat diets both significantly reduce hepatic steatosis : A randomized controlled trial", Hepatology, 68, pp.1741~1754 (2018)
116. Pugliese N, "Is there an ‘ideal’ diet for patients with NAFLD?", Eur J Clin Invest, 52, pp.e13659~ (2022)
117. Yaskolka Meir A, "Effect of green-Mediterranean diet on intrahepatic fat : the DIRECT PLUS randomised controlled trial", Gut, 70, pp.2085~2095 (2021)
118. Chen YP, "A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease", Clin Nutr, 38, pp.2552~2557 (2019)
119. Wijarnpreecha K, "Coffee consumption and risk of nonalcoholic fatty liver disease : a systematic review and meta-analysis", Eur J Gastroenterol Hepatol, 29, pp.e8~e12 (2017)
120. Diniz TA, "Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-α signaling in obese mice", Life Sci, 266, pp.118868~ (2021)
121. Zheng F, "Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γand genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet", Lipids Health Dis, 18, pp.6~ (2019)
122. Cao H, "Adipocytokines in obesity and metabolic disease", J Endocrinol, 220, pp.T47~T59 (2014)
123. Ennequin G, "Role of exercise-induced hepatokines in metabolic disorders", Am J Physiol Endocrinol Metab, 317, pp.E11~E24 (2019)
124. Pugh CJ, "Exercise training reverses endothelial dysfunction in nonalcoholic fatty liver disease", Am J Physiol Heart Circ Physiol, 307, pp.H1298~H1306 (2014)
125. Kistler KD, "Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease", Am J Gastroenterol, 106, pp.460~468 (2011)
126. Rinella ME, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease", Hepatology, 77, pp.1797~1835 (2023)
127. Villareal DT, "Aerobic or resistance exercise, or both, in dieting obese older adults", N Engl J Med, 376, pp.1943~1955 (2017)
128. García-Hermoso A, "Concurrent aerobic plus resistance exercise versus aerobic exercise alone to improve health outcomes in paediatric obesity : a systematic review and metaanalysis", Br J Sports Med, 52, pp.161~166 (2018)
129. Liu X, "A preliminary study of the effects of Tai Chi and Qigong medical exercise on indicators of metabolic syndrome, glycaemic control, health-related quality of life, and psychological health in adults with elevated blood glucose", Br J Sports Med, 44, pp.704~709 (2010)
130. Singh AK, "Partitioning of radiological, stress and biochemical changes in pre-diabetic women subjected to Diabetic Yoga Protocol", Diabetes Metab Syndr, 13, pp.2705~2713 (2019)
131. Thorp A, "Exercise as medicine : The IMPACT of exercise training on nonalcoholic fatty liver disease", Curr Hepatol Rep, 19, pp.402~411 (2020)
132. Fakhry TK, "Bariatric surgery improves nonalcoholic fatty liver disease : a contemporary systematic review and meta-analysis", Surg Obes Relat Dis, 15, pp.502~511 (2019)
133. Wiggins T, "Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level : A systematic review and meta-analysis", PLoS Med, 17, pp.e1003206~ (2020)
134. Bazerbachi F, "Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis", Clin Gastroenterol Hepatol, 19, pp.146~154 (2021)
135. Elsaid MI, "Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease", JAMA Netw Open, 5, pp.e2235003~ (2022)
136. Krishnan A, "Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity", JAMA Netw Open, 6, pp.e237188~ (2023)
137. Gollisch KS, "EndoBarrier gastrointestinal liner in type 2 diabetic patients improves liver fibrosis as assessed by liver elastography", Exp Clin Endocrinol Diabetes, 125, pp.116~121 (2017)
138. Lee YM, "Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis : a pilot study", Gastrointest Endosc, 76, pp.756~760 (2012)
139. Jirapinyo P, "Effect of endoscopic bariatric and metabolic therapies on nonalcoholic fatty liver disease : A systematic review and metaanalysis", Clin Gastroenterol Hepatol, 20, pp.511~524 (2022)
140. Stefan N, "Non-alcoholic fatty liver disease : causes, diagnosis, cardiometabolic consequences, and treatment strategies", Lancet Diabetes Endocrinol, 7, pp.313~324 (2019)
141. Vuppalanchi R, "Therapeutic pipeline in nonalcoholic steatohepatitis", Nat Rev Gastroenterol Hepatol, 18, pp.373~392 (2021)
142. Alkhouri N, "The TONIC trial : a step forward in treating pediatric nonalcoholic fatty liver disease", Hepatology, 55, pp.1292~1295 (2012)
143. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
144. Usman M, "Vitamin E as an adjuvant treatment for non-alcoholic fatty liver disease in adults : A systematic review of randomized controlled trials", Cureus, 12, pp.e9018~ (2020)
145. Sato K, "Vitamin E has a beneficial effect on nonalcoholic fatty liver disease : a meta-analysis of randomized controlled trials", Nutrition, 31, pp.923~930 (2015)
146. Xu R, "Association between vitamin E and non-alcoholic steatohepatitis : a meta-analysis", Int J Clin Exp Med, 8, pp.3924~3934 (2015)
147. Bril F, "Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes : A randomized controlled trial", Diabetes Care, 42, pp.1481~1488 (2019)
148. Miller ER 3rd, "Meta-analysis : high-dosage vitamin E supplementation may increase all-cause mortality", Ann Intern Med, 142, pp.37~46 (2005)
149. Lonn E, "Effects of long-term vitamin E supplementation on cardiovascular events and cancer : a randomized controlled trial", JAMA, 293, pp.1338~1347 (2005)
150. Klein EA, "Vitamin E and the risk of prostate cancer : the Selenium and Vitamin E Cancer Prevention Trial(SELECT)", JAMA, 306, pp.1549~1556 (2011)
151. Cheng P, "Vitamin E intake and risk of stroke : a meta-analysis", Br J Nutr, 120, pp.1181~1188 (2018)
152. Schürks M, "Effects of vitamin E on stroke subtypes : meta-analysis of randomised controlled trials", BMJ, 341, pp.c5702~ (2010)
153. Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis(FLINT) : a multicentre, randomised, placebocontrolled trial", Lancet, 385, pp.956~965 (2015)
154. Younossi ZM, "Obeticholic acid for the treatment of nonalcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
155. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
156. Chitturi S, "The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2 : Management and special groups", J Gastroenterol Hepatol, 33, pp.86~98 (2018)
157. Marchesini G, "Response to : Comment to"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease"", J Hepatol, 66, pp.466~467 (2017)
158. Momtazi-Borojeni AA, "The role of PCSK9 in NAFLD", NASH and therapeutic implications of PCSK9 inhibition, 2022, pp.15, 1199~1208
159. Duseja A, "Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease(NAFLD)not responding to lifestyle interventions", Ann Hepatol, 6, pp.222~226 (2007)
160. Loomba R, "Clinical trial : pilot study of metformin for the treatment of non-alcoholic steatohepatitis", Aliment Pharmacol Ther, 29, pp.172~182 (2009)
161. Torres DM, "Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans : a 12-month randomized, prospective, open-label trial", Hepatology, 54, pp.1631~1639 (2011)
162. Li Y, "Metformin in non-alcoholic fatty liver disease : A systematic review and meta-analysis", Biomed Rep, 1, pp.57~64 (2013)
163. Musso G, "Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease(NAFLD) : a systematic review and meta-analysis of randomised trials", Diabetologia, 55, pp.885~904 (2012)
164. Sawangjit R, "Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD):A PRISMA-compliant systematic review and network metaanalysis", Medicine(Baltimore), 95, pp.e4529~ (2016)
165. Belfort R, "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis", N Engl J Med, 355, pp.2297~2307 (2006)
166. Blazina I, "Diabetes drugs for nonalcoholic fatty liver disease : a systematic review", Syst Rev, 8, pp.295~ (2019)
167. Bril F, "Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes", Clin Gastroenterol Hepatol, 16, pp.558~566 (2018)
168. Bugianesi E, "Insulin resistance in nonalcoholic fatty liver disease", Curr Pharm Des, 16, pp.1941~1951 (2010)
169. Gastaldelli A, "From NASH to diabetes and from diabetes to NASH : Mechanisms and treatment options", JHEP Rep, 1, pp.312~328 (2019)
170. Dougherty JA, "A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease", Ann Pharmacother, 55, pp.65~79 (2021)
171. Mann JFE, "Liraglutide and renal outcomes in type 2 diabetes", N Engl J Med, 377, pp.839~848 (2017)
172. Marso SP, "Liraglutide and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 375, pp.311~322 (2016)
173. Armstrong MJ, "Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis(LEAN) : a multicentre, doubleblind, randomised, placebo-controlled phase 2 study", Lancet, 387, pp.679~690 (2016)
174. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
175. Zhu Y, "Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease : A systematic review and meta-analysis", Front Endocrinol(Lausanne), 12, pp.769069~ (2021)
176. Nespoux J, "SGLT2 inhibition and kidney protection", Clin Sci(Lond), 132, pp.1329~1339 (2018)
177. Palmiero G, "Impact of SGLT2 inhibitors on heart failure : From pathophysiology to clinical effects", Int J Mol Sci, 22, pp.5863~ (2021)
178. Ohki T, "Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1analogs and dipeptidyl peptidase-4 inhibitors", Clin Drug Investig, 36, pp.313~319 (2016)
179. Seko Y, "Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus", Hepatol Res, 47, pp.1072~1078 (2017)
180. Ito D, "Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes : A randomized, 24-week, open-label, active-controlled trial", Diabetes Care, 40, pp.1364~1372 (2017)
181. Akuta N, "Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of nonalcoholic fatty liver disease complicated by diabetes mellitus", Hepatol Res, 49, pp.531~539 (2019)
182. Shimizu M, "Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease", Diabetes Obes Metab, 21, pp.285~292 (2019)
183. Chehrehgosha H, "Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes : A randomized, double-blind, placebocontrolled clinical trial", Diabetes Ther, 12, pp.843~861 (2021)
184. Wong C, "Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in Asian patients with type 2 diabetes : A meta-analysis", Front Endocrinol(Lausanne), 11, pp.609135~ (2021)
185. Xing B, "Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes : A metaanalysis of randomized controlled trials", J Diabetes Investig, 11, pp.1238~1247 (2020)
186. Dwinata M, "SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus : a systematic review", Clin Exp Hepatol, 6, pp.339~346 (2020)
187. Langley AK, "Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus", Pharmacotherapy, 27, pp.1163~1180 (2007)
188. Avogaro A, "The effects of dipeptidyl peptidase-4inhibition on microvascular diabetes complications", Diabetes Care, 37, pp.2884~2894 (2014)
189. Hattori S, "Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus", Diabetol Metab Syndr, 13, pp.117~ (2021)
190. Clifton P, "Do dipeptidyl peptidase IV(DPP-IV)inhibitors cause heart failure?", Clin Ther, 36, pp.2072~2079 (2014)
191. Fu AZ, "Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes : An observational study", Diabetes Care, 39, pp.726~734 (2016)
192. Yang TY, "Association of Sitagliptin with cardiovascular outcome in diabetic patients : a nationwide cohort study", Acta Diabetol, 53, pp.461~468 (2016)
193. Smits MM, "Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes : a randomised placebo-controlled trial", Diabetologia, 59, pp.2588~2593 (2016)
194. Olaywi M, "Novel anti-diabetic agents in non-alcoholic fatty liver disease : a mini-review", Hepatobiliary Pancreat Dis Int, 12, pp.584~588 (2013)
195. Ha KH, "Comparative cardiovascular risks of dipeptidyl peptidase-4 inhibitors : Analyses of real-world data in Korea", Korean Circ J, 48, pp.395~405 (2018)
196. Tani S, "Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin : a pilot study", Am J Cardiovasc Drugs, 13, pp.443~450 (2013)
197. Tsochatzis E, "Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors : a comparative approach with genotype 1 chronic hepatitis C", Dig Liver Dis, 39, pp.936~942 (2007)
198. Peleg N, "Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load", JHEP Rep, 1, pp.9~16 (2019)
199. Wang X, "Metabolic dysfunction-associated fatty liver disease(MAFLD)and viral hepatitis", J Clin Transl Hepatol, 10, pp.128~133 (2022)
200. Hu D, "Nonalcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model", Hepatol Int, 12, pp.438~446 (2018)
201. Choi HSJ, "Nonalcoholic steatohepatitis is associated with liverrelated outcomes and all-cause mortality in chronic hepatitis B", Hepatology, 71, pp.539~548 (2020)
202. Koike K, "Metabolic aspects of hepatitis C viral infection : steatohepatitis resembling but distinct from NASH", J Gastroenterol, 40, pp.329~336 (2005)
203. Chen CH, "Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy", Hepatol Int, 7, pp.162~170 (2013)
204. Lonardo A, "Steatosis and hepatitis C virus : mechanisms and significance for hepatic and extrahepatic disease", Gastroenterology, 126, pp.586~597 (2004)
205. Younossi ZM, "Obesity and non-alcoholic fatty liver disease in chronic hepatitis C", J Clin Gastroenterol, 38, pp.705~709 (2004)
206. Petta S, "Cardiovascular diseases and HCV infection : a simple association or more?", Gut, 63, pp.369~375 (2014)

관련 논문AI추천